Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

NKTX

HOLDREMOVE

Nkarta, Inc. · Healthcare · United States · $205M · Avg Vol: $2M/d

42
StockRank
Q
34
V
35
M
64
P/E (TTM)
—
ROE
-30.1%
D/E
0.3x
Dividend %
—
Director Trades · 180d
−$4.8K →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

Nkarta is a clinical-stage biotech company with no approved products or revenues. This does not meet our criteria for high-quality compounders with predictable owner earnings.

COMPANY DESCRIPTION

Nkarta, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf, engineered natural killer (NK) cell therapies for cancer. Its proprietary NK cell platform aims to overcome limitations of other cell therapies by offering scalable, allogeneic treatments with broad applicability across various cancers. Nkarta is a pioneering biotechnology firm focused on advancing the next generation of cancer immunotherapy through innovative NK cell technology.

FINANCIAL SUMMARY (USD)

Year20212022202320242025CAGR
Revenue00000—
EPS-2.62-2.61-2.40-1.60-1.41—
Shares33.0M48.9M49.2M70.6M71.1M+115.6%
Debt12.5M82.9M88.3M80.3M76.4M57.4%
Equity251.0M372.2M273.3M408.0M312.3M5.6%
Op CF-67.9M-57.0M-86.2M-99.7M-88.7M—
Inv CF32.5M-184.7M79.0M-129.6M100.3M—
Fin CF1.2M219.0M0.7M226.1M0.1M—
Loading...
PRICE (1Y)-11.9%
2.432.652.873.083.30May 12Jun 3Jun 24
SMA 50SMA 200
Close
$2.89
RSI (14)
54.7
52W High
$3.65
From 52W High
0.8%

SCORE BREAKDOWN

Quality
34
ROIC
-31.9%21.4
ROE
-30.1%25.2
GP/Assets
—N/A
Op. Margin
0.0%40.3
FCF/Assets
-14.2%23.2
Piotroski
12.4
Int. Cover
—N/A
D/E Ratio
0.26x46.8
Current Ratio
12.96x90.9
Value
35
P/E (TTM)
—N/A
EV/EBITDA
-0.5x25.0
P/FCF
—N/A
P/B
0.7x91.4
P/S
—N/A
Div Yield
—N/A
Momentum
64
52W High %
79%70.8
RS 6M
53%92.9
SMA 50/200
1.26x91.6
EPS Rev 4W
0.0%49.2
EPS Rev 12W
+3.6%56.1
EPS Improve
-27%12.6
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$205M
P/E (Forward)
-1.7x
Gross Margin
0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NKTX are excluded.

TickerCompanyMkt CapStockRankSignal
NKTXNkarta, Inc.(you)$205M42HOLD
EQEquillium, Inc.$185M41HOLD
UNCYUnicycive Therapeutics, Inc.$210M39HOLD
DTILPrecision BioSciences, Inc.$179M43HOLD
IMUXImmunic, Inc.$199M48HOLD
KPTIKaryopharm Therapeutics Inc.$202M34SELL
ELDNEledon Pharmaceuticals, Inc.$313M42HOLD
VTVTvTv Therapeutics Inc.$132M41HOLD
ANTXAN2 Therapeutics, Inc.$191M33SELL
AGENAgenus Inc.$126M40HOLD

Peer medians: ROE -23.1% · P/E 25.2x · Gross margin 44.3%

Nkarta, Inc. (NKTX) — Stock Score Summary

Nkarta, Inc. (NKTX) has a MoatMap StockRank of 42/100 based on Quality (34/100), Value (35/100), and Momentum (64/100) factor scores. The current signal is HOLD. Nkarta is a clinical-stage biotech company with no approved products or revenues. This does not meet our criteria for high-quality compounders with predictable owner earnings.

Nkarta, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf, engineered natural killer (NK) cell therapies for cancer. Its proprietary NK cell platform aims to overcome limitations of other cell therapies by offering scalable, allogeneic treatments with broad applicability across various cancers. Nkarta is a pioneering biotechnology firm focused on advancing the next generation of cancer immunotherapy through innovative NK cell technology.

Key Financial Metrics

Price$2.89
Market Cap$205M
P/E (Forward)-1.67
Price/Book0.72
Return on Equity-30.1%
Return on Invested Capital-31.9%
Debt/Equity26.24
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-57M

Nkarta, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Nkarta, Inc.’s (NKTX) StockRank?
MoatMap’s StockRank for Nkarta, Inc. (NKTX) is 42/100, with a Hold signal. It is a composite of Quality (34), Value (35), and Momentum (64) factor ranks across MoatMap’s 20,000+ stock universe.
Does Nkarta, Inc. have an economic moat?
Nkarta, Inc. (NKTX) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Nkarta, Inc. a buy, hold, or sell?
MoatMap’s current signal for Nkarta, Inc. (NKTX) is Hold, based on a StockRank of 42/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Nkarta, Inc. in?
Nkarta, Inc. (NKTX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksNKTX deep dive reportAI ChampionsHow we score stocksSense-check another stock